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Background: The clinical need to be able to administer high doses of intravenous iron 
  conveniently as a rapid infusion has been addressed by the recent introduction of ferric 
  carboxymaltose and subsequently iron isomaltoside 1000. Neither requires a test dose. 
The   maximum dose of ferric carboxymaltose is 1000 mg. The maximum dose of iron   isomaltoside 
1000 is based on 20 mg/kg body weight without a specified ceiling dose, thereby increasing 
the scope of being able to achieve total iron repletion with a single infusion. This ability to 
give high doses of iron is important in the context of managing iron deficiency anemia, which 
is associated with a number of clinical conditions where demands for iron are high. It is also an 
important component of the strategy as an alternative to blood transfusion. Affordability is a key 
issue for health services. Recent price changes affecting iron sucrose and ferric carboxymaltose, 
plus modifications to the manufacturers’ prescribing information, have provoked this update.
Methods: This study is a comparative analysis of the costs of acquiring and administering 
the newly available intravenous iron formulations against standard treatments in the hospital 
setting. The costs include the medication, nursing costs, equipment, and patient transportation. 
Three dosage levels (600 mg, 1000 mg, and 1600 mg) are considered.
Results and conclusion: The traditional standard treatments, blood and iron sucrose, cost more 
than the alternative intravenous iron preparations across the dose spectrum and sensitivities. Low 
molecular weight iron dextran is the least expensive option at the 1600 mg dose level but has 
the caveat of a prolonged administration time and requirement for a test dose. At 600 mg and 
1000 mg dose levels, both iron isomaltoside 1000 and ferric carboxymaltose are more   economical 
than low molecular weight iron dextran. Iron isomaltoside 1000 is less expensive than ferric 
carboxymaltose at all dose levels. Newly available iron preparations appear to be clinically 
promising, cost effective, and practical alternatives to current standards of iron repletion.
Keywords: iron isomaltoside 1000, ferric carboxymaltose, iron deficiency anemia, single high 
dose, IV iron, cost minimization
Introduction
The ability to administer high doses of intravenous (IV) iron rapidly, without the need 
for a test dose, is an important development in the strategy for treating iron deficiency 
anemia (IDA). Ferric carboxymaltose was the first IV iron to be introduced to the 
UK that did not require a test dose. It can be given rapidly and administered at up to 
20 mg per kg body weight to a ceiling of 1000 mg per infusion.1 Iron isomaltoside 
1000, whilst also administered rapidly, can be administered at up to 20 mg of iron per Therapeutics and Clinical Risk Management  2011:7 submit your manuscript | www.dovepress.com
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kg of body weight.2 The absence of a specific dose ceiling for 
iron isomaltoside 1000 offers the opportunity to deliver very 
high doses (total doses) in a single administration.2 This may 
be of practical importance when calculating the treatment 
dose based on the Ganzoni formula that incorporates amounts 
for replenishing body iron stores.3 Doses for a number of 
disorders associated with IDA commonly require doses well 
in excess of 1000 mg.4–8
A prerequisite for undertaking a cost minimization 
study is establishing similarity of outcome from the treat-
ment options.9 Iron treatment may be considered a “basic 
physiological requirement” (a micronutrient).10 There is 
no evidence to indicate that the choice of IV iron formula-
tion affects the physiological uptake or iron metabolism. 
Thus, whilst the literature provides evidence of efficacy (as 
measured by a range of measurable outcomes) for each of 
the IV iron treatment options (including blood), there are 
no comparative data to suggest a physiological difference 
in performance.11–15 It is also recognized that the legacy of 
adverse events (ADEs) experienced with Imferon® (Fisons, 
Ipswich, UK),16 a high molecular weight iron dextran for-
mulation withdrawn from the European market almost two 
decades ago, has been superseded by subsequent treatments 
which are associated with low levels of similar ADEs and, as 
such, any costs associated with ADEs are likely to be similar 
across the treatment options.1,2,16–19
The low level of ADEs associated with the two latest 
introductions (ferric carboxymaltose and iron isomaltoside 
1000) is reflected in their approved modes of administration, 
as neither require the administration of a test dose.1,2 Patients 
receiving iron sucrose require a test dose prior to receiving 
their first dose.18 Those receiving low molecular weight iron 
dextran require a test dose at the time of each administra-
tion.19 The purpose of a test dose is to predose (challenge) 
with a small amount of iron (eg, 20–25 mg) of the chosen 
formulation followed by a period of observation to establish 
the likelihood of the formulation provoking an ADE. A test 
dose, followed by an observation period, extends the overall 
administration time and cost (nurse observation time). The 
arrival of two formulations where a test dose is explicitly 
excluded increases convenience (for both patients and health 
care professionals), reduces the overall administration time, 
and, furthermore, implicitly endorses the safety profile of 
the latest IV iron therapy options.1,2
The original paper examining the comparative costs of 
IV iron therapy and standard blood transfusions was first 
published in March 2011.20 However, a subsequent modifica-
tion in the price of two of the products included in the initial 
analysis reduced the validity of the results. This subsequent 
study reflects the changed product acquisition costs, the 
current price of blood in England and Wales, and the most 
recently published nursing costs.
Background
Blood is a declining resource. The safety associated with the 
receipt of a blood infusion has progressively improved over 
the last decade but there are recognized risks (and costs) 
associated with a blood transfusion.21 Strategies to reduce the 
risks have led to the imposition of restrictions on members 
of the population who can be blood donors. This has resulted 
in a decline in the volume of blood donated. Additionally, 
following the identification of blood-borne diseases in blood 
donated by UK donors (eg, prion-related diseases, including 
Creutzfeldt–Jakob disease), certain cohorts of the popula-
tion are prevented from receiving blood and blood products 
prepared from blood donated in the UK.
The National Blood Transfusion Service has encouraged 
the conservation and appropriate use of blood and blood 
products.15 The policy of reducing inappropriate blood use 
is aimed at reducing both the intrinsic risks associated with 
blood and risks associated with the process of matching and 
administration.
These developments have been at a time when the impor-
tance, implications, and prevalence of IDA is being appreci-
ated and associated with a broad range of clinical conditions 
and situations, for example, in:
•	 chronic kidney disease patients, including renal trans-
plant patients with/without erythropoietin replacement 
therapy
•	 patients undergoing various modes of dialysis therapy
•	 anemia associated with pregnancy (pre/postpartum, fol-
lowing hemorrhage)
•	 anemia following “high blood loss” surgical procedures; 
eliminating or reducing the need for postsurgery transfu-
sion (eg, orthopedics, colorectal surgery)
•	 the elderly (often iron deficient and/or anemic); especially 
prior to surgery where blood loss may be significant
•	 IDA associated with anemia of chronic disease
•	 chronic IDA (often presenting with acute symptoms)
•	 chronic occult blood loss (inflammatory bowel disease)
•	 anemia associated with cancer or the use of chemothera-
peutic agents
•	 menorrhagia (heavy uterine bleeding)
•	 chronic heart failure.
In these situations, iron-store repletion provides the 
substrate for erythropoiesis, thereby restoring or   improving Therapeutics and Clinical Risk Management  2011:7
Table 1 Comparative intravenous drip infusion regimens1,2,18,19,27
Product Iron sucrose Low molecular  
weight iron dextran
Iron isomaltoside  
1000
Ferric carboxymaltose Blood
Dose limitation 100 mg or 200 mg 100–200 mg 20 mg/kg body weight to total  
body weight
20 mg/kg up to max  
1000 mg
none
Rate of  
administration
100 mg in 15 mins 
200 mg in 30 mins
100 mg in 37.5 mins 
200 mg in 41.25 mins
0–5 mg/kg body weight in 15 mins 
6–10 mg/kg body weight in 30 mins 
11–20 mg/kg body weight in 60 mins
100 mg to 200 mg no  
minimum time quoted 
$200–500 mg 6 mins 
$500–1000 mg 15 mins
i unit  
(equ 200 mg  
iron) 90 mins
Test dose Required for first  
administration
Required at each  
administration
not required not required n/A
Abbreviations: equ, equivalent; n/A, not applicable.
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hemoglobin levels. This can commonly be achieved without 
the need for concomitant erythropoiesis-stimulating therapy.22
Anemia of chronic disease may be a comorbidity associ-
ated with a number of chronic conditions (eg, rheumatoid 
arthritis, inflammatory bowel disease). In these conditions, 
where hepcidin blocks both the absorption of iron from the 
gastrointestinal tract and mobilization of stored iron, IV iron 
has been demonstrated to bypass these blocks.23,24
Compared with oral iron, IV iron repletes iron stores 
more rapidly and can be given at high doses, as a total dose 
infusion, which improves compliance.2,19,25 Oral iron is 
associated with poor tolerance, poor compliance, and a high 
frequency of ADEs.26 It is poorly absorbed in patients with 
anemia of chronic disease and does not appear to bypass 
the immobilized iron stores.23,24 As such, its role as a useful 
source of iron supplementation is limited and its low cost 
often a “false economy.” However, in spite of such caveats, 
it is still commonly used as first-line iron supplementation 
for patients diagnosed with chronic kidney disease.
The administration of IV iron may be considered a more 
physiological method of addressing chronic IDA than a blood 
transfusion. A transfusion addresses the acute symptoms of 
anemia, but is a poor and expensive source of iron, whereas 
IV iron provides physiologically available iron for both 
erythropoiesis and replenishing iron stores.
The purpose of this paper is to examine the comparative 
cost to the health care economy of the IV iron supplementation 
options, including blood transfusion. The economic impor-
tance is driven by the need to optimize the use of services 
in the current challenging financial climate whilst serving 
the needs of patients and maintaining patient safety. In these 
circumstances, value for money and the overall relative cost 
of treatments are important when making policy prescribing 
decisions. Given that all options will achieve similar clinical 
responses, a cost minimization analysis was undertaken to 
determine the least expensive option overall. 
Methods
The costs of administering iron isomaltoside 1000 and ferric 
carboxymaltose are compared with the cost of administering 
a blood transfusion, iron sucrose, and low molecular weight 
iron dextran across a range of doses in a secondary care 
(hospital) setting. The cost model includes transportation, 
nursing, and equipment costs.
Initially, three matrix spreadsheets were established 
(one at each dose level) for the total costs of   administering 
each of the options incorporating the sensitivity   parameters 
(transport 10% and 20% of patients) and nurse grade6 (nurse 
team leader) and 7 (nurse team manager) (ie, four total costs 
for each treatment option at the three dose levels).
From these, for each treatment option, and at each dose 
level, a mean cost was established with the maximum and 
minimum levels taken from their respective sensitivity cal-
culations (Table 4). This allowed a comparison to be made 
and provided an indication of the level of robustness of the 
relative costs.
Cost differences between each of the three traditional 
treatments were calculated with reference to each of the 
two recently introduced formulations using the mean costs 
with the differences calculated as an absolute and percentage 
difference (Table 5).
Finally, a direct “head to head” comparison at each 
dose level was undertaken between the mean cost of ferric 
carboxymaltose and iron isomaltoside 1000 that provides 
the actual and percentage differences for each dose level 
(Table 6).
Parameters for the revised cost model
Standard treatment comparators
Standard treatment will vary according to local practice 
and medical specialty. Traditionally, blood would have 
been the sole option in most of the indications/situa-
tions described. IV iron is used almost exclusively in Therapeutics and Clinical Risk Management  2011:7
Table 3 Comparative high dose infusion regimens1,2,18,19
Product Iron sucrose Low molecular weight  
iron dextran
Iron isomaltoside  
1000
Ferric carboxymaltose Blood
Dose limitation 200 mg 20 mg/kg 20 mg/kg 20 mg/kg max 1000 mg n/A
Rate of  
administration
n/A* 20 mg/kg first 25 mg (test dose)  
over 15 mins then balance over 4 hours
0–10 mg/kg in 30 mins 
11–20 mg/kg in 60 mins
$200–500 mg 6 mins 
$500–1000 mg 15 mins
n/A
Test dose n/A Required at each administration not required not required n/A
Note: *Requires multiple administrations of 200 mg intravenous injections to deliver total dose.
Abbreviation: n/A, not applicable.
Table 2 Comparative intravenous injection regimens1,2,18,19
Product Iron sucrose Low molecular weight  
iron dextran
Iron isomaltoside  
1000
Ferric carboxymaltose Blood
Dose limitation 200 mg 200 mg 200 mg 1000 mg n/A
Rate of  
administration
100 mg in 5 mins  
minimum – 10 mins maximum 
200 mg in 10 mins  
minimum – 20 mins maximum
100 mg in 25 mins 
200 mg in 35 mins
2–4 mins .200–500 mg at 100 mg/min 
500–1000 mg over 15 mins
n/A
Test dose Required for first  
administration
Required at each  
administration
not required not required n/A
Abbreviation: n/A, not applicable.
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hemodialysis patients, whereas, in other situations, IV iron 
is progressively replacing the practice of administering a 
blood transfusion.
As a standard treatment, blood is included as a com-
parator. Iron sucrose (considered a standard treatment) 
and low molecular weight iron dextran are also used as 
comparators.
Dose levels
The comparator doses were chosen to reflect clinical practice. 
Blood is transfused in multiples of “units.” Each unit may be 
considered to approximate 200 mg of elemental iron.
Iron doses are commonly calculated using the Ganzoni 
formula.3 It is not uncommon for an individual’s requirement 
to be up to 2000 mg or higher across the range of conditions 
associated with anemia.4–8
For the purposes of this cost minimization modeling, 
three levels of administration were chosen (to provide a dose 
sensitivity matrix): 600 mg, 1000 mg, and 1600 mg. These 
allowed direct comparison with units of blood.
Bioavailability and efficacy
In preparing this cost minimization model, it was assumed 
that each of the IV iron preparations impact erythropoiesis 
and enter iron stores in a similar manner directly related to 
the dose administered. There is no evidence to suggest that 
incorporation of iron into reticulocytes, elevation of hemo-
globin levels, and development of iron stores differs.28–32
The administration of IV iron differs physiologically to 
the administration of a blood transfusion. Blood results in 
an immediate rise in hemoglobin level. Iron from a blood 
transfusion is then recycled as the erythrocytes expire, but the 
resulting elevation in iron stores and hemoglobin level are 
considered to be similar for the purposes of this study.
ADEs
In the cost modeling, no allowance was made for occurrence 
of ADEs. These are infrequent and similar for iron sucrose 
and low molecular weight iron dextran.17–19 The summaries 
of product characteristics for iron isomaltoside 1000 and 
ferric carboxymaltose indicate that ADEs associated with 
their use will be similar to those of currently available IV 
iron formulations.1,2,18,19
Blood has higher levels of risk, both as a product per se 
and from the potential human error associated with compat-
ibility testing and administration. However, no cost has been 
allocated to the treatment of these ADEs.
Dose and rate of administration limitations
In the cost modeling, the dose (including any constraints), rate 
of administration, and need for a test dose were taken from 
the manufacturers’ prescribing information (Tables 1–3).
The manufacturers’ instructions for undertaking a test dose 
were carefully incorporated into the modeling. For example, in 
the case of low molecular weight iron dextran, when admin-
istered for the first time, a 25 mg dose is given and the patient Therapeutics and Clinical Risk Management  2011:7 submit your manuscript | www.dovepress.com
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observed for 45 minutes.19 The balance can then be administered 
if there are no ADEs. For the second and subsequent infusions, 
the first 25 mg of iron is infused over 15 minutes and, if there 
are no untoward events, the administration can be continued.19 
When a total dose is administered, the patient should be 
observed for a further hour after the completion of the admin-
istration.19 For the administration of iron sucrose, a test dose is 
required only for the first administration to a patient.18
For the purposes of this study, it was assumed that this 
was the second (or subsequent) administration to a patient of 
iron sucrose and low molecular weight iron dextran. For the 
specified range of doses, an observation period was included in 
the administration times for low molecular weight iron dextran 
(as indicated in the manufacturer’s prescribing information).19 
Given the recommended dilution volume for preparing 
the infusion, it was assumed that the administration plus 
observation period would be similar at each dose level – that 
is, 6 hours in total. In this analysis, 10 minutes was allowed 
for setup time across the range of preparations.
Transportation
This is an important factor when considering IV iron 
supplementation. Across the spectrum of patients with IDA, 
a proportion will be short of breath, perhaps with palpitations; 
will invariably be nonambulatory; and will be transported to 
hospital on a stretcher or in a wheelchair. Additionally, a number 
will be elderly, frail, and disabled. In the UK, ambulance ser-
vices are paid for by the National Health Service. Two types 
of “transported” patient are considered: (1) those who are 
ambulatory, where the charge is GBP£12.00/single journey 
(GBP£24.00 return) and (2) those who are in a wheelchair or 
who require a stretcher where the charge for a single journey 
is GBP£48.00 single (GBP£96.00 return).33
Across the spectrum of causes of IDA, it is difficult to 
establish the specific proportion of patients who require trans-
portation and the ratio between ambulatory and nonambulatory 
patients. In this study, a sensitivity of 10% and 20% of patients 
requiring treatment is used. These percentages are to reflect 
transport requirements across the spectrum of patients with IDA. 
Table 4 Mean (with maximum and minimum range) comparative treatment costs for administering intravenous iron at three dose 
levels (600 mg, 1000 mg and, 1600 mg)
Comparative costs, GBP£
Iron sucrose Low molecular weight  
iron dextran
Iron isomaltoside  
1000
Ferric  
carboxymaltose
Blood
600 mg iron
Mean 261.61 221.19 170.21 173.23 449.80
Min 241.61 206.88 163.54 164.94 442.67
Max 281.61 235.49 176.87 181.52 456.92
1000 mg iron
Mean 436.02 253.07 231.71 249.63 737.55
Min 402.68 238.76 225.50 241.34 727.67
Max 469.35 267.37 237.92 257.92 747.42
1600 mg iron
Mean 697.63 300.89 333.41 404.86 1169.17
Min 644.29 286.58 327.20 394.27 1155.17
Max 750.96 315.19 339.62 415.44 1183.17
Table 5 Relative cost position (mean) of iron isomaltoside 1000 and ferric carboxymaltose at three dose levels compared to standard 
treatments and blood
Cost difference, GBP£ (±%)
Iron isomaltoside 1000 vs  
iron sucrose
Iron isomaltoside 1000 vs  
low molecular weight iron dextran
Iron isomaltoside 1000 vs   
blood
600 mg dose −91.40 (−34.93%) −50.98 (−23.05%) −279.59 (−62.16%)
1000 mg dose −204.31 (−46.86%) −21.36 (−8.44%) −505.84 (−68.58%)
1600 mg dose −364.22 (−52.21%) +32.52 (+10.81%) −835.76 (−71.48%)
Ferric carboxymaltose vs  
Iron sucrose
Ferric carboxymaltose vs  
low molecular weight iron dextran
Ferric carboxymaltose vs   
blood
600 mg dose −88.38 (−33.78%) −47.96 (−21.68%) −276.57 (−61.49%)
1000 mg dose −186.39 (−42.75%) −3.44 (−1.36%) −487.92 (−66.15%)
1600 mg dose −292.77 (−41.97%) +103.97 (+34.55%) −764.31 (−65.37%)Therapeutics and Clinical Risk Management  2011:7
Table 6 Relative cost position (mean) of iron isomaltoside 1000 versus ferric carboxymaltose at three dose levels of iron (600 mg, 
1000 mg and, 1600 mg)
Mean cost iron isomaltoside  
1000 (GBP£)
Mean cost ferric carboxymaltose  
(GBP£)
Mean cost saving iron isomaltoside  
1000 vs ferric carboxymaltose (GBP£)
600 mg dose 170.21  173.23 3.02 (1.74%)
1000 mg dose 231.71 249.63 17.92 (7.18%)
1600 mg dose 333.41 404.86 71.45 (17.65%)
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For example, few anemic pregnant women will require transport, 
but there will be a high demand for transportation by those 
undergoing dialysis or elderly persons undergoing surgery. It 
is assumed that those requiring transport will be equally split 
between those who are ambulatory and those who are nonam-
bulatory (who require a stretcher or wheelchair).
Giving sets, cannula, and dressing
For the purpose of this analysis, unit costs reported by 
Bhandari and Naudeer34 were used. These were GBP£7.89 
for a “giving set,” GBP£0.74 for one cannula, and GBP£0.54 
for a standard dressing.
nursing time
The costs for 1 hour of patient-contact nursing time in the 
UK at midband 6 and 7 have risen to GBP£70.00 (+4.5%) 
and GBP£81.00 (+5.2%), respectively, and reflect the latest 
figures published by the Personal Social Services Research 
Unit (2009/10).35,36 Nurse grades 6 (nurse team leader) 
and 7 (nurse team manager) are used to reflect the level of 
knowledge, experience, and responsibility required to run a 
nurse-led “anemia” service.
In the cost allocations, assumptions are made with regard 
to allocating time to represent multitasking (ie, not dedicating 
sole time to an individual patient during a 6-hour low molecular 
weight iron dextran total dose infusion administration). Thus, 
for a short administration (approximately 30 minutes) time, a 
nurse is likely to attend for the duration. For an infusion taking 
about 60 minutes it is assumed that the nurse will spend 50% 
of their time with the patient, whereas, for a prolonged infusion 
of low molecular weight iron dextran, a nurse is considered to 
spend 33% of their time with the patient. (During the test-dose 
phase and observation phase this may be 100%.) The differ-
ences in administration times are reflected in the nursing time 
and, therefore, nurse costs required for the administration of 
each treatment option at each dose level.
Cost of iV iron products
Recent price modifications are now used. For 200 mg iron, 
these are GBP£18.70 (+10%) for iron sucrose,37 GBP£15.94 
for low molecular weight iron dextran,38 GBP£38.20 
(−12.2%) for ferric carboxymaltose,39 and GBP£33.90 for 
iron isomaltoside 1000.40
Cost of blood
The cost used in this modeling is now updated to that charged 
in England and Wales to NHS hospitals for 2010/11, which 
is GBP£125.00/unit (−6.37%) for red blood cells. (This does 
not include the cost of pretransfusion cross matching of a 
patient’s blood or error checking.41)
Other costs
Expenditure considered minor or unlikely to be significant 
to the outcomes was excluded. This can be justified on the 
basis that, in any particular unit, the practice is likely to 
have a similar impact across the IV iron options. A cost 
deliberately omitted was that of the clinician. Whilst 
likely to be available during a transfusion, they would be 
undertaking other clinical/administrative duties, whereas 
a nurse would normally be responsible for administering 
the infusion and managing/monitoring the procedure. 
An example of a minor cost not included is that of the 
infusion fluid (normal saline), which costs GBP£0.70 
per 250 mL.34
Results
From Table 4, it is observed that both iron isomaltoside 
1000 and ferric carboxymaltose are the lower cost options 
when compared with iron sucrose and blood at each dose 
level and across all levels of sensitivity. When compared 
with low molecular weight iron dextran, both have a lower 
cost at the 600 mg and 1000 mg level, however, at the 
1600 mg dose level, low molecular weight iron dextran 
offers a lower cost than both ferric carboxymaltose and iron 
isomaltoside 1000.
This same table indicates that low molecular weight iron 
dextran is less expensive than iron sucrose across the dose 
spectrum and across the sensitivity ranges. Blood is the 
highest cost option and this is without including the costs 
of cross matching.Therapeutics and Clinical Risk Management  2011:7 submit your manuscript | www.dovepress.com
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The actual cost and percentage differences accruing from 
using either iron isomaltoside 1000 or ferric carboxymaltose 
compared with the current standard treatments are illustrated 
in Table 5. It is apparent throughout that greater savings 
are potentially realizable by adopting iron isomaltoside 
1000 instead of ferric carboxymaltose and, on the single occa-
sion that a traditional therapy is less expensive (ie, 1600 mg 
dose of low molecular weight iron dextran), the saving is 
GBP£103.97 compared with ferric carboxymaltose but only 
GBP£32.52 when compared with iron isomaltoside 1000.
A direct comparison of the cost of using the latest two 
entrants at the three dose levels is presented in Table 6. The 
potential expenditure savings from using iron isomaltoside 
1000 at each dose level range from GBP£3.02 at the 600 mg 
dose level (1.74%), to GBP£71.45 at the 1600 mg dose level 
(17.65%).
Discussion
Blood continues to be used to treat IDA, in the absence of 
acute blood loss, associated with a number of conditions. 
This is against NHS Blood and Transplant policies to reduce 
blood use, which include the use of IV iron as an alterna-
tive to blood.15 There is, however, momentum gaining pace 
toward treating IDA with iron supplementation (normally 
with IV iron).
Renal medicine has been at the forefront of pioneering the 
use of IV iron. This practice historically developed following 
the introduction of iron sucrose. Iron sucrose can be adminis-
tered in doses of up to 200 mg in a single administration and, 
as such, it was adopted in hemodialysis units. It is normally 
given to patients during one of their weekly hemodialysis ses-
sions. This use of IV iron has resulted in a dramatic reduction 
in the requirement for blood transfusion.
The results of this updated cost minimization modeling 
(Tables 4 and 5) indicate that each of the IV iron options are 
less expensive than administering a blood transfusion at each 
iron repletion level and thereby may further encourage the 
consideration of iron as an alternative to blood in patients 
with IDA, especially in those diagnosed with chronic IDA.
Iron sucrose is well established as a standard treatment 
for IDA, however, its use is constrained by the maximum 
amount that can be given in a single administration. This is 
particularly pertinent when considering total iron repletion 
requirements. The Ganzoni formula is widely used to calcu-
late these requirements.3 This formula embraces repletion of 
iron stores (frequently 500 mg of iron). The resulting dose 
calculation, depending on the weight of the patient, prevailing 
hemoglobin level, target hemoglobin level, and cause of IDA, 
may be well above 1000 mg and may exceed 2000 mg. To 
achieve repletion with iron sucrose would require multiple 
administrations of 200 mg doses, which is impractical and 
inconvenient. Furthermore, apart from blood, it is the least 
attractive option from a cost perspective across the dose range 
under consideration.
Since the withdrawal of Imferon® (high molecular weight 
iron dextran), low molecular weight iron dextran, available 
in the UK since the 1990s, has been at the forefront for cli-
nicians wishing to administer large doses of iron at a single 
clinic visit. However, the prolonged infusion time may be 
considered a disadvantage both for the health service provider 
and the patient.
In this analysis, low molecular weight iron dextran has 
been shown to be less expensive than the standard treat-
ments of blood and iron sucrose across the dose range. When 
compared to the more recently introduced options (ferric 
carboxymaltose and iron isomaltoside 1000) it is more expen-
sive at the 600 mg and 1000 mg dose levels. At the 1600 mg 
dose level, ferric carboxymaltose is 34.6% more expensive 
to administer. Whilst iron isomaltoside 1000 is also more 
expensive, the difference is much less at 10.8% (GBP£32.52) 
and may perhaps be preferred (and justified) given the 
much reduced time required for administration, patient 
convenience, and potential increase in patient throughput 
(especially in the “payment by results” environment).
The direct comparison between iron isomaltoside 1000 
and ferric carboxymaltose (Table 6) suggests that iron 
isomaltoside 1000 offers potential savings when compared 
with ferric carboxymaltose at all three dose levels but espe-
cially at the higher dose end of the spectrum.
In the modeling, key “drivers” are cost of medication, 
time for administration (affecting nurse resource), and 
transportation. The cost of the various iron formulations are 
National Health Service acquisition costs. The choice of 
available IV treatment options is limited to those included 
in this analysis.
This analysis has not embraced oral iron supplementation. 
It is acknowledged that oral iron has a significant role in 
preventing and treating IDA and has a much lower cost than 
either IV iron formulations or blood. However, the patient 
population that receive IV iron or blood is largely defined as 
those for whom oral iron is not appropriate, where oral iron 
has not been tolerated, has resulted in an unacceptable level 
of side effects, where compliance is poor, or where treatment 
has not achieved target iron parameters (ie, hemoglobin or 
ferritin levels).1,2,18,19 There is evidence to indicate that IV 
iron will achieve target parameters more quickly than oral Therapeutics and Clinical Risk Management  2011:7 submit your manuscript | www.dovepress.com
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iron and, more importantly, when compared with oral iron, 
overcomes the “hepcidin block” affecting iron absorption and 
mobilization of iron stores in patients where IDA is associated 
with chronic conditions.23–25 The ability to give a total dose 
repletion rapidly, in a single infusion, overcomes compli-
ance issues and is highly convenient for a number of patient 
types (eg, the elderly, in pregnancy). It may be justified on 
the basis of achieving target hemoglobin and ferritin levels 
more rapidly than oral iron – for example, prior to elective 
surgery – thereby reducing the incidence of cancellations 
due to poor anemic status.
Conclusion
Parenteral iron treatment has advanced significantly as a result 
of the introduction of ferric carboxymaltose and subsequently 
iron isomaltoside 1000. The scope for administering rapid 
single high doses of iron, without the need for a test dose, to 
address IDA associated with various clinical conditions, is 
a welcome development. This further enhances the prospect 
of using IV iron as an alternative to a blood transfusion for 
treating chronic IDA. This may be particularly important in 
the strategy of reducing blood use and reducing the incidence 
and volume of blood transfusions in the UK. It is particularly 
pertinent to note that this can be undertaken at a cost well 
below that of blood.
This updated analysis confirms that blood as a source 
of iron is expensive and is the least attractive option from a 
cost perspective. Iron sucrose, in addition to being able to 
be administered only in small 200 mg doses and requiring 
a test dose, is more expensive than the other available IV 
iron alternatives. Only at the highest dose level (1600 mg) 
does low molecular weight iron dextran offer cost savings 
worthy of any consideration compared with the two newest 
entrants.
Ferric carboxymaltose has a lower cost than iron sucrose 
and blood across the dose range; is only noticeably more 
expensive than low molecular weight iron dextran at the 
1600 mg level, where the cost difference has to be bal-
anced against administration time, convenience, and patient 
throughput. It is, however, more expensive than iron isomalto-
side 1000 at each dose level (progressively, GBP£3.02 at 
600 mg, GBP£17.92 at 1000 mg, and GBP£71.45 at the 
1600 mg dose levels).
Likewise, iron isomaltoside 1000 has a lower cost than 
iron sucrose and blood across the dose range; it compares 
favorably with low molecular weight iron dextran at the 
600 mg and 1000 mg dose levels but is marginally more 
expensive at the 1600 mg level. Cost savings compared to 
ferric carboxymaltose prevail across the dose range but are 
less pronounced than previously published following this 
product’s price reduction.
This analysis of the relative holistic cost of administer-
ing the treatment options endeavors to more closely reflect 
the “real world” situation when making prescribing policy 
decisions associated with the treatment of IDA.
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